Gossamer Bio Inc (GOSS)

There is no doubt that Gossamer Bio Inc (GOSS) ticks all the boxes. – Sete News - SETE News

SETE News

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society ... - Business Wire

Business Wire

Ratio Review: Analyzing Gossamer Bio Inc (GOSS)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

The Dwinnex

Gossamer Bio, Inc. Forecasted to Earn FY2028 Earnings of $0.24 Per Share (NASDAQ:GOSS) - MarketBeat

MarketBeat

Gossamer Bio Inc (GOSS) is a good investment, but the stock may be undervalued – US Post News - US Post News

US Post News

FY2028 EPS Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS) Reduced by Analyst - Defense World

Defense World

Wedbush Weighs in on Gossamer Bio, Inc.'s Q1 2025 Earnings (NASDAQ:GOSS) - Defense World

Defense World

Brokers Set Expectations for Gossamer Bio, Inc.'s Q3 2024 Earnings (NASDAQ:GOSS) - Defense World

Defense World

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Business Wire

Leerink Partnrs Analysts Lift Earnings Estimates for Gossamer Bio, Inc. (NASDAQ:GOSS) - MarketBeat

MarketBeat

Q2 2024 Earnings Estimate for Gossamer Bio, Inc. (NASDAQ:GOSS) Issued By Wedbush - Defense World

Defense World

Wedbush Weighs in on Gossamer Bio, Inc.'s Q2 2024 Earnings (NASDAQ:GOSS) - MarketBeat

MarketBeat

Gossamer Bio, Inc. Expected to Post Q1 2024 Earnings of ($0.25) Per Share (NASDAQ:GOSS) - Defense World

Defense World

Gossamer Bio (NASDAQ:GOSS) Rating Reiterated by Wedbush - MarketBeat

MarketBeat

It is Poised to be a Bull Market for Gossamer Bio Inc (GOSS) – Sete News - SETE News

SETE News

Market Watch: Gossamer Bio Inc (GOSS)'s Noteworthy Drop, Closing at 0.73 – DWinneX - The Dwinnex

The Dwinnex

Gossamer Bio's (GOSS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Defense World

Gossamer Bio: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Gossamer Bio (NASDAQ:GOSS) Rating Reiterated by Wedbush - MarketBeat

MarketBeat

Latham Watkins Advises Gossamer Bio in Global Collaboration With Chiesi - Latham & Watkins LLP

Latham & Watkins LLP

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update - Business Wire

Business Wire

Gossamer Bio and Chiesi Group Announce Global Collaboration - European Pharmaceutical Manufacturer

European Pharmaceutical Manufacturer

Gossamer Bio and Chiesi link on pulmonary hypertension treatment - Pharmaceutical Technology

Pharmaceutical Technology

Gossamer Bio and Chiesi Group Announce Global Collaboration - European Pharmaceutical Manufacturer

European Pharmaceutical Manufacturer

Gossamer Bio (NASDAQ:GOSS) Given "Buy" Rating at HC Wainwright - MarketBeat

MarketBeat

Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide - AOL

AOL

Chiesi and Gossamer Bio Partner to Develop & Commercialize Seralutinib - Contract Pharma

Contract Pharma

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment - 1470 & 100.3 WMBD

1470 & 100.3 WMBD

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment - WKZO

WKZO

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment - KFGO

KFGO

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment - KDAL

KDAL

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment - WTVB

WTVB

Gossamer Bio Forms Major Alliance with Chiesi Farmaceutici - TipRanks.com - TipRanks

TipRanks

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize ... - Business Wire

Business Wire

Gossamer Bio, Chiesi form seralutinib PH treatment alliance - Investing.com

Investing.com

Gossamer Bio reports positive phase 2 trial results for PAH treatment - Investing.com UK

Investing.com UK

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine - Business Wire

Business Wire

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine - Yahoo Finance

Yahoo Finance

Gossamer Bio Decline Means Insider Profits Down To US$17k - Yahoo Finance

Yahoo Finance

Gossamer Bio Inc (GOSS) did well last session? – US Post News - US Post News

US Post News

Gossamer Bio Inc (GOSS) Becoming More Attractive for Investors – Knox Daily - Knox Daily

Knox Daily

Examining Gossamer Bio Inc (GOSS)'s cash flow and debt position – DWinneX - The Dwinnex

The Dwinnex

Gossamer Bio COO/CFO sells $7430 in company stock - Investing.com

Investing.com

Gossamer Bio executive sells over $5000 in company stock - Investing.com

Investing.com

The Escalator: BioNTech, Theseus, Gossamer Bio and more - MM+M Online

MM+M Online

Gossamer Bio expands board with medical and financial experts - Investing.com Canada

Investing.com Canada

Should You Buy Gossamer Bio (GOSS) After Golden Cross?

Zacks Investment Research

Should You Buy Gossamer Bio (GOSS) After Golden Cross? - Yahoo Finance

Yahoo Finance

Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know

Benzinga

Goldman Sachs Maintains Buy Rating for Gossamer Bio: Here's What You Need To Know - Markets Insider

Markets Insider